FDMT Insider Charles Theuer Buys 50,000 Shares

Insider Buying and Selling at 4D Molecular Therapeutics, Inc.

On June 17, 2026, Charles Theuer purchased 50,000 shares of 4D Molecular Therapeutics, Inc. (FDMT) on the NasdaqGS exchange. At the time of the trade, the stock was priced at $9.66. This acquisition adds to the growing trend of insider buying at the company, signaling confidence from its leadership.

A Wave of Insider Purchases

Theuer wasn't the only insider making moves on that day. Other executives at 4D Molecular also bought shares, including John Milligan, who acquired 75,000 shares, and Shawn Tomasello, Nancy Miller-Rich, Jacob Chacko, Susannah Gray, and Glenn Sblendorio, each buying 50,000 shares. This collective action suggests a strong belief in the company's prospects among its leadership.

How 4D Molecular Therapeutics, Inc. Stock Has Traded

Currently, 4D Molecular Therapeutics trades significantly below its 52-week high of $16.93. The stock's previous close was $15.22, and with the recent insider buying, it may attract further attention. The company has a market capitalization of approximately $841.9 million, indicating its scale within the biotechnology sector.

Analysts Set New Price Targets

On October 6, 2026, Chardan Capital maintained a Buy rating for FDMT, with a price target of $25. Earlier, on September 29, B of A Securities also maintained a Buy rating but raised its target to $33, up from $29. Additionally, Cantor Fitzgerald upgraded its rating to Overweight with a target of $20 on September 14. The consensus among analysts is a strong buy, with a target mean price of $27.82 based on 11 analyst opinions.

What 4D Molecular Therapeutics, Inc. Does

4D Molecular Therapeutics, based in Emeryville, California, is a late-stage biotechnology company focused on developing innovative gene therapies using adeno-associated virus vectors. Its lead product candidate aims to treat retinal vascular diseases, highlighting the company's commitment to addressing significant health issues.

What’s Next for 4D Molecular?

Investors will be watching closely as 4D Molecular prepares for its next earnings report on November 10, 2026. This upcoming announcement will be crucial for understanding the company's financial health and future direction. The recent insider trades reflect a strong belief in the company's long-term potential, although the 13F filings may not represent current positions.